Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions
Zubair A, Rethana M, Ma A, McAlpine L, Abulaban A, Munro B, Patwa H, Nowak R, Roy B. Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions. Journal Of Clinical Neuromuscular Disease 2023, 25: 11-17. PMID: 37611265, DOI: 10.1097/cnd.0000000000000439.Peer-Reviewed Original ResearchConceptsNeuro-immunological diseaseIntravenous immunoglobulinAutoimmune neurological disordersAutoimmune neuromuscular disorderAdult patientsElderly patientsNeurological disordersNeuromuscular disordersChronic inflammatory demyelinating polyradiculoneuropathyNational Inpatient Sample databaseNational Inpatient Sample datasetInflammatory demyelinating polyradiculoneuropathySafe therapeutic choiceRetrospective chart reviewAppropriate clinical settingSide effect profileDemyelinating polyradiculoneuropathyIVIG useChart reviewYounger patientsMyasthenia gravisEffect profileMedical historyPrimary diagnosisTherapeutic choiceNeurological sequelae of vaccines
McAlpine L, Zubair A. Neurological sequelae of vaccines. Neurological Sciences 2023, 44: 1505-1513. PMID: 36622478, PMCID: PMC9838503, DOI: 10.1007/s10072-022-06581-z.Peer-Reviewed Original ResearchMeSH KeywordsEncephalomyelitis, Acute DisseminatedGuillain-Barre SyndromeHumansMyelitis, TransverseVaccinationVaccinesConceptsGuillain-Barre syndromeInfectious diseasesNeurological sequelaeAcute disseminated encephalomyelitisSystemic immune activationMild adverse reactionsDisseminated encephalomyelitisLocal sorenessNeurologic sequelaeTransverse myelitisAdverse eventsRecent vaccinationImmune activationAdverse reactionsDisease onsetPotential pathogenesisSafe optionPotential treatmentEarly identificationVaccineSequelaeRapid diagnosisAdverse effectsTypical symptomsDisease